Tao Jiang is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
In connection with the consummation of the initial business combination of Tradeup Acquisition Corp. ("UPTD", together with its successor, Estrella Immunopharma, Inc., the "Issuer") pursuant to certain business combination agreement by and among UPTD, Tradeup Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of UPTD, and Estrella Biopharma, Inc., a Delaware corporation ("Estrella"), UPTD changed its name to Estrella Immunopharma, Inc. This "Exit" Form 4 is voluntarily filed to report that the Reporting Person is no longer serving in the role as the Issuer's Director effectively or holding more than 10% of issued and outstanding shares of the Issuer after September 29, 2023, and is therefore no longer subject to Section 16 Reporting.